These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9764784)

  • 41. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
    Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.
    Blanco JL; Biglia MA; Arnedo M; Martínez E; Mallolas J; Milinkovic A; Laguno M; Larrousse M; Leon A; Lonca M; García F; Miró JM; Pumarola T; Gatell JM
    AIDS; 2005 May; 19(8):829-31. PubMed ID: 15867498
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures.
    Campo RE; Moreno JN; Suarez G; Miller N; Kolber MA; Holder DJ; Shivaprakash M; DeAngelis DM; Wright JL; Schleif WA; Emini EA; Condra JH
    AIDS; 2003 Sep; 17(13):1933-9. PubMed ID: 12960826
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
    Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
    Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life.
    Eriksson LE; Bratt GA; Sandström E; Nordström G
    Health Qual Life Outcomes; 2005 May; 3():32. PubMed ID: 15871738
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
    Lebbé C; Blum L; Pellet C; Blanchard G; Vérola O; Morel P; Danne O; Calvo F
    AIDS; 1998 May; 12(7):F45-9. PubMed ID: 9619797
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ritonavir-saquinavir rescue therapy in HIV-positive patients failing with indinavir, rotinavir or saquinavir.
    De Wit S; Cassano P; Hermans P; Sommereijns B; Kabeya K; O'Doherty E; Clumeck N
    AIDS; 1999 Sep; 13(13):1794-5. PubMed ID: 10509591
    [No Abstract]   [Full Text] [Related]  

  • 48. Nutritional status changes in HIV-infected children receiving combined antiretroviral therapy including protease inhibitors.
    Fiore P; Donelli E; Boni S; Pontali E; Tramalloni R; Bassetti D
    Int J Antimicrob Agents; 2000 Nov; 16(3):365-9. PubMed ID: 11091066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A review of low-dose ritonavir in protease inhibitor combination therapy.
    Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW
    Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virological treatment failure of highly active antiretroviral therapy in an unselected cohort of HIV-infected patients.
    Bonfanti P; Capetti A; Di Mattei P; Niero F; Rizzardini G
    AIDS; 1998 Jun; 12(9):1111. PubMed ID: 9662213
    [No Abstract]   [Full Text] [Related]  

  • 53. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
    Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S
    HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Long-term immunologic response in HIV-infected patients with CD4 cell counts Le Moing V; Eid Z; Ecobichon JL; Duval X; Longuet P; Elbim C; Brun-Vezinet F; Leport C; Vilde JL
    Ann Med Interne (Paris); 2001 Feb; 152(1):11-4. PubMed ID: 11240420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.
    Rolla VC; da Silva Vieira MA; Pereira Pinto D; Lourenço MC; de Jesus Cda S; Gonçalves Morgado M; Ferreira Filho M; Werneck-Barroso E
    Clin Drug Investig; 2006; 26(8):469-79. PubMed ID: 17163279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Storm DS; Boland MG; Gortmaker SL; He Y; Skurnick J; Howland L; Oleske JM;
    Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort.
    Kirk O; Gerstoft J; Pedersen C; Nielsen H; Obel N; Katzenstein TL; Mathiesen L; Lundgren JD
    HIV Med; 2001 Jan; 2(1):43-51. PubMed ID: 11737375
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
    Tebas P; Patick AK; Kane EM; Klebert MK; Simpson JH; Erice A; Powderly WG; Henry K
    AIDS; 1999 Feb; 13(2):F23-8. PubMed ID: 10202820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.